QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer

NCT06917092 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Endometrial Adenocarcinoma
Endometrial Cancer

Interventions

DRUG: QL1706 combined with chemotherapy ± Bevacizumab

Sponsor

Tianjin Medical University Cancer Institute and Hospital